Pfizer Inc. (NYSE:PFE) Shares Bought by Moloney Securities Asset Management LLC

Moloney Securities Asset Management LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 314.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 71,600 shares of the biopharmaceutical company's stock after acquiring an additional 54,332 shares during the period. Moloney Securities Asset Management LLC's holdings in Pfizer were worth $1,814,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its holdings in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 2,087 shares during the period. Inceptionr LLC acquired a new stake in Pfizer in the fourth quarter valued at $229,000. AlphaQuest LLC lifted its holdings in Pfizer by 26.1% in the fourth quarter. AlphaQuest LLC now owns 24,083 shares of the biopharmaceutical company's stock valued at $639,000 after acquiring an additional 4,987 shares during the period. Finally, Independent Advisor Alliance lifted its holdings in Pfizer by 5.7% in the fourth quarter. Independent Advisor Alliance now owns 247,805 shares of the biopharmaceutical company's stock valued at $6,574,000 after acquiring an additional 13,350 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on PFE shares. UBS Group raised their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Wolfe Research raised their target price on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. Redburn Atlantic cut their price target on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. TD Cowen cut their price target on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research note on Tuesday, April 22nd. Finally, Bank of America lifted their price target on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $28.55.

Pfizer Trading Down 0.5%

Shares of NYSE:PFE traded down $0.13 during trading on Friday, reaching $25.65. 34,838,317 shares of the stock were exchanged, compared to its average volume of 41,815,668. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The firm has a market cap of $145.83 billion, a price-to-earnings ratio of 18.59, a price-to-earnings-growth ratio of 0.93 and a beta of 0.58. The firm's 50-day moving average price is $23.86 and its 200 day moving average price is $24.81.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same quarter in the previous year, the business earned $0.82 EPS. The company's revenue for the quarter was down 7.8% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.71%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.